George Stouffer is a Cardiology physician. OpenAlex indexes 526 publications with 7,188 citations (h-index 44); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
101 Manning Dr
Chapel Hill, ND 275990001
Telephone
919-966-4131Registry record last updated 24 Jun 2008.
Clinical trials
- Daily Step-based Exercise Using Fitness Monitors for Peripheral Artery Disease
Sponsor: University of North Carolina, Chapel Hill
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)Program year20251 payment
- Amgen Inc.Program year20251 payment
- Medtronic, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
78.7%Statin18.4%Atorvastatin Calcium62%Rosuvastatin Calcium38%Part D≥26 patientsBeta blocker11%Metoprolol Succinate85%Metoprolol Tartrate15%Part D<11 patients+ 11 more classes in this area
Blood & clotting
19.1%P2Y12 inhibitor15%Clopidogrel63%Prasugrel Hcl37%Part D<11 patientsFactor Xa inhibitor4.1%Eliquis62%Xarelto38%Part D<11 patientsMetabolism & gastrointestinal
2.2%SGLT2 inhibitor2.2%Farxiga100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy
Frontiers in Cardiovascular Medicine
2022 - Impact of the <i>CYP2C19*17</i> Allele on Outcomes in Patients Receiving Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Clinical Pharmacology & Therapeutics
2020 - Clinical Utility of <i>CYP2C19</i> Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention
Arteriosclerosis Thrombosis and Vascular Biology
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”